References
Gittes RF. Carcinoma of the prostate. N Engl J Med 1991; 324:236–245.
Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000; 163:1632–1642.
Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, J. Czernin J, Maddahi J, Phelps ME. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997; 27:94–106.
Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer 1997; 80 (Suppl):1595–1607.
Hricak H, Schoder H, Pucar D, Lis E, Eberhardt SC, Onyebuchi CN, Scher HI. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol 2003; 30:616–634.
Silverman JM, Krebs TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol 1997; 168:379–385.
Hara T, Kosaka TL, Shinoura N, Kondo T. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 1997; 38:842–847.
Roivainen A, Forsback S, Gronroos T, Lehikoinen P, Kahkonen M, Sutinen E, Minn H. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000; 27:25–32.
Hara T.11C-choline and 2-deoxy-2-[18F]fluoro-d-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 2002; 4:267–273.
Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, Hautmann R, Reske SN. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000; 27:1415–1419.
Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39:990–995.
Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, Minn H. Kinetics of [11C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2003; 31:317–324.
de Jong IJ, Pruim J, Elsinga PH, Vaalburg H, Mensink HJ. Visualization of prostate cancer with11C-choline positron emission tomography. Eur Urol 2002; 42:18–23.
de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by11C-choline PET. J Nucl Med 2003; 44:331–335.
de Jong, IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ.11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003; 44:32–38.
Picchio M., Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, Matarrese M, Matei DV, De Cobelli F, Del Maschio A, Rocco F, Rigatti P, Fazio F. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169:1337–1340.
Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39:990–995.
Picchio M, Landoni C, Messa C, Gianolli L, Matarrese M, De Cobelli F, Maschio A, Fazio F. Positive [11C]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer. AJR Am J Roentgenol 2002; 179:482–484.
Ak I, Stokkel MP, Pauwels EK. Positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 2000; 126: 560–574.
Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36:31–35.
Thomas CT, Bradshaw PT, Pollock BH, Montie JE, Taylor JM, Thames HD, McLaughlin PW, DeBiose DA, Hussey DH, Wahl RL. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003; 21:1715–1721.
Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, Meyer GJ, Karstens JH, Knapp WH, Boerner AR. Positron emission tomography with11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003; 30:607–611.
Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, Kibel AS, Andriole GL, Picus J. Welch, M.11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44:556–558.
Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, Shinohara N, Katoh C, Nakada K, Tamaki N. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 2002; 29:1492–1495.
Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K.11C-acetate PET imaging of prostate cancer. J Nucl Med 2002; 43:181–186.
Kotzerke J, Volkmer BG, Glatting G, van den Hoff J, Gschwend JE, Messer P, Reske SN, Neumaier B. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003; 42:25–30.
Dimitrakopoulou-Strauss A, Strauss LG. PET imaging of prostate cancer with11C-acetate. J Nucl Med 2003; 44:549–555.
Wawroschek F, Wengenmair H, Senekowitsch-Schmidtke R, Hamm M, Henke J, Schonberger T, Hauser A, Erhardt W, Harzmann R. Prostate lymphoscintigraphy and radioguided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003; 70:303–310.
Coleman R, DeGrado T, Wang S, Baldwin S, Orr M, Reiman R, Price D. Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 2000; 3:147.
DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, Reiman R, Price DT, Coleman RE. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42:1805–1814.
Pelosi E, Messa C, Sironi S, Picchio M, Landoni C, Bettinardi V, Gianolli L, Del Maschio A, Gilardi MC, Fazio F. Value of integrated PET/CT for lesion localization in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 2004; 31:in press. DOI 10.1007/s00259-004-1483-3.
Author information
Authors and Affiliations
Corresponding author
Additional information
The opinions expressed within the Controversies section represent the views of the authors only.
Rights and permissions
About this article
Cite this article
Fazio, F., Picchio, M. & Messa, C. Is 11C-choline the most appropriate tracer for prostate cancer?. Eur J Nucl Med Mol Imaging 31, 753–755 (2004). https://doi.org/10.1007/s00259-004-1542-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-004-1542-9